Company Overview and News

1
Asanko Gold: New Life After Joint Venture With Gold Fields

2018-09-26 seekingalpha - 1
Nevertheless, the company's future performance remains unclear, under the current share price dynamics reflect this uncertainty.
GFI.WI AKG GFI GFIOF AKG

 
Joint Asanko Gold and Gold Fields Presentation and Webcast at the Denver Gold Forum

2018-09-19 globenewswire
VANCOUVER, British Columbia, Sept. 19, 2018 (GLOBE NEWSWIRE) -- Asanko Gold Inc. (“Asanko” or the “Company”) (TSX, NYSE American: AKG) President and CEO, Peter Breese and Gold Fields Limited (JSE/NYSE: GFI) CEO, Nick Holland will host a joint presentation and webcast with analysts and investors at the Denver Gold Forum at 7:25 am MDT on Monday, September 24, 2018. Details below.
GFI.WI AKG GFI GFIOF AKG

25
GDX: It's A Bear Market, You Know

2018-08-08 seekingalpha
The Gold Miners Index has made another 52-week low and continues to trade in a bear market.
NGD KGI KGI.DB.A KGI.DB NGDAF NGD RGLD SBGL.WI AKG ELD GORO PGLC AKG KL EGO RGL

 
Thor Explorations Announces Appointment of Adrian Coates as Chairman and Addition of Collin Ellison as Non-Executive Director to Board

2018-08-06 globenewswire
VANCOUVER, British Columbia, Aug. 06, 2018 (GLOBE NEWSWIRE) -- Thor Explorations Ltd. (TSX VENTURE: THX) (“Thor” or the “Company”) is pleased to announce the appointment of Adrian Coates as Non-Executive Chairman with immediate effect. Adrian joined the Company’s board as a Non-executive Director in December 2016 and has been Chairman of the Company’s audit committee since February 2017.
11IE RPT PLZLY 42KM AKG 42MA RGORF GOLD THX RRS AKG GOLD

4
Conscious Capitalism Is Planting Its Roots In The Investment Market

2018-07-13 seekingalpha
Companies that do not actively participate in sustainable business practices are considered out of touch - and, in extreme cases, unethical.
WPM ABX AKG ROGFF GG TU AKG ABX

3
Asanko Gold Announces Q2 2018 Production Results

2018-07-12 globenewswire - 3
VANCOUVER, British Columbia, July 12, 2018 (GLOBE NEWSWIRE) -- Asanko Gold Inc. (“Asanko” or the “Company”) (TSX:AKG) (NYSE American:AKG) announces production results for the second quarter (“Q2”) of 2018 from the Asanko Gold Mine (“AGM”), located in Ghana, West Africa.
AKG AKG

9
Asanko Gold Receives Ghana Government Approval for US$185 Million Gold Fields Joint Venture Transaction

2018-06-22 globenewswire - 1
VANCOUVER, British Columbia, June 22, 2018 (GLOBE NEWSWIRE) -- Asanko Gold Inc. (“Asanko” or the “Company”) (TSX:AKG) (NYSE MKT:AKG) is pleased to announce that it has received approval from the Ghanaian Minister of Lands and Natural Resources, whose approval was the principal condition to the closing of Asanko’s previously announced joint venture transaction (the “Transaction”) with Gold Fields Limited (JSE, NYSE: GFI) for a 50% interest in Asanko’s 90% interest in the Asanko Gold Mine in Ghana, West Africa.
GFI.WI AKG GFI GFIOF AKG

12
Asanko Gold Results of Annual General Meeting

2018-06-08 globenewswire - 5
VANCOUVER, British Columbia, June 08, 2018 (GLOBE NEWSWIRE) -- Asanko Gold Inc. (“Asanko” or the “Company”) (TSX:AKG) (NYSE MKT:AKG) announced that all the resolutions put to shareholders at the Company’s annual general meeting (the “Meeting”) held on June 8, 2018 were duly passed. The results for each of the matters voted upon at the Meeting are set out below:
AKG AKG

18
Gold Fields Will Play Smart In 2019 And Beyond

2018-06-08 seekingalpha - 1
However Golf Fields' financial performance and strong portfolio of mining assets indicate a promising outlook beyond the one-year horizon.
AULGF GFI.WI AKG AU GFI AGG GFIOF AKG

9
Gold Fields to set aside acquisitions, sees industry costs rising-CEO

2018-05-30 reuters - 1
LIMA, May 30 (Reuters) - South Africa’s Gold Fields is setting aside pursuit of new acquisitions for a year as it focuses on its existing operations and nearby prospects instead, the bullion producer’s chief executive told Reuters late on Tuesday.
GFI.WI AKG GFI GFIOF AKG

10
Asanko Gold' (AKG) CEO Peter Breese on Q1 2018 Results - Earnings Call Transcript

2018-05-11 seekingalpha - 2
Good morning, ladies and gentlemen, and welcome to the Asanko Gold Q1 2018 Operating and Financial Results Conference Call and Webcast, which is being recorded. A copy of today's press release, the management discussion and analysis, and the presentation is available on the company's website at www.asanko.com.
GFI.WI AKG GFI GFIOF AKG

10
Asanko Gold Inc. 2018 Q1 - Results - Earnings Call Slides

2018-05-10 seekingalpha - 3
The following slide deck was published by Asanko Gold Inc. in conjunction with their 2018 Q1 earnings call.
AKG AKG

7
Asanko Gold Publishes 2017 Corporate Social Responsibility Report 

2018-05-07 globenewswire
VANCOUVER, British Columbia, May 07, 2018 (GLOBE NEWSWIRE) -- Asanko Gold Inc. (“Asanko” or the “Company”) (TSX:AKG) (NYSE American:AKG) today publishes its 2017 Corporate Social Responsibility (“CSR”) Report, which provides a detailed review of Asanko’s CSR strategy and performance during the year, including its contribution to both the local communities in which it operates and its host country, Ghana.
AKG AKG

9
Asanko Gold Annual General Meeting Information

2018-05-03 globenewswire - 2
VANCOUVER, B.C., May 03, 2018 (GLOBE NEWSWIRE) -- Asanko Gold Inc. (“Asanko” or the “Company”) (TSX:AKG) (NYSE MKT:AKG) advises it will hold its Annual General Meeting of shareholders (“AGM”) on Friday June 8, 2018 at 10am PDT, in Vancouver, B.C., Canada.
AKG AKG

9
Asanko Gold Announces Q1 2018 Production Results

2018-04-19 globenewswire - 2
VANCOUVER, British Columbia, April 19, 2018 (GLOBE NEWSWIRE) -- Asanko Gold Inc. (“Asanko” or the “Company”) (TSX:AKG) (NYSE American:AKG) announces production results for the first quarter (“Q1”) of 2018 from the Asanko Gold Mine (“AGM”), located in Ghana, West Africa.
AKG AKG

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...